NEWS
Go back
ARCHIMED HEALTHCARE IT sells global digital health solutions provider Ametris to Signant Health
May
28,
2026
Under ARCHIMED HEALTHCARE IT stewardship, Ametris (formerly ActiGraph) was transformed from a US-based hardware-led actigraphy specialist into a global software-led leader in FDA-approved digital endpoints and decentralized clinical trials, serving the top 25 pharmaceutical companies across 150-plus countries.
ARCHIMED HEALTHCARE IT, part of global private equity healthcare specialist ARCHIMED, announces the sale of Ametris, held by its MED II fund, to Signant Health, the global leader in eCOA and eClinical solutions. The transaction unifying Ametris’ wearable-derived digital outcome measures with Signant’s patient-reported outcomes leadership, closes a gap in digital measures, positioning Signant as a purpose-built, end-to-end clinical evidence platform for the pharmaceutical industry.
Founded in 2004, Ametris is a global digital health solutions provider that transforms real-world patient data into validated clinical evidence based on proprietary algorithms and hundreds of corresponding publications. Its end-to-end platform combines advanced wearables, regulatory-aligned analytics and expert scientific support. Ametris supported more than 260 industry-sponsored trials across 150-plus countries and serves the top 25 pharmaceutical companies. The business operates at the forefront of a structural shift in clinical research — from subjective measures toward continuous, sensor-derived digital endpoints accepted by regulators — a $1.1 billion market growing double digits annually.
When ARCHIMED acquired ActiGraph in 2020, the company was a hardware-led actigraphy specialist serving mostly academia and some pharma. With management, ARCHIMED rebranded it as Ametris and transformed it into a software-led, pharma-grade and pharma-focused digital endpoints leader.
ARCHIMED HEALTHCARE IT’s value creation journey rested on three MedValue levers: internationalization, innovation and M&A. ARCHIMED’s playbook was deployed through the ARCHIMED BUSINESS SYSTEM (“ABS”) to help making those changes happen while most Ametris competitors failed on the exact same challenges. Ametris evolved from a US-anchored specialist into a global platform serving most of the world’s top pharmaceutical companies with solutions developed specifically for corresponding Therapeutic Areas and Diseases. ARCHIMED built out a science-led management team, backed the launch of LEAP – the next-generation biometric sensor that received FDA 510(k) clearance in October 2023 – and supported the creation of the DECODE consortium, generating proprietary biomarker IP in indications including obesity and nocturnal scratch. In October 2024, Ametris carved out and acquired Biofourmis Connect, making the platform device-agnostic and adding critical algorithms to its offering.
“Ametris is a textbook example of ARCHIMED’s playbook: source a science-driven business at an inflection point and scale it into a global category leader,” says Robin Filmer-Wilson, Partner at ARCHIMED. “Signant Health is the natural next home — together they create the integrated, multimodal evidence platform sponsors have been asking for.”
“Ametris is a textbook example of ARCHIMED’s playbook: source a science-driven business at an inflection point and scale it into a global category leader,”
Robin Filmer-Wilson, Partner ARCHIMED
“ARCHIMED has been the right partner for this journey,” says Jeremy Wyatt, CEO of Ametris who remains in his position post-transaction. “Their international expansion expertise and network allowed us to globalize and transform Ametris from a US to a truly international player.
ARCHIMED’s MED II, the fund which acquired Ametris, was raised in 2018 and invested in 11 companies through majority buyout transactions. MED II has sold seven companies, already returning 2x cash-to-cash to Investors and is at 2.7x TVPI.
MED II is ranked in the top 5% of all buyout funds for its 2018 vintage, according to data from Preqin. Previous 2014 vintage fund is ranked as the best Buyout fund at global level for its vintage. All other deployed ARCHIMED Buyout funds (2019, 2021 and 2022) are also top quartile performers.
ARCHIMED was ranked 11th best Buyout firm globally out of 695 Private Equity firms and 1,439 funds raised between 2012 and 2021 in the last by Dow Jones-HEC Performance Ranking report, reflecting the depth, maturity, and stability of ARCHIMED’s approach to specialized global healthcare investing.